ARCHIVES

FDA Rile Changes Reporting Requirements for Adverse Events

This article is from The Cancer Letter archive.

Vol. 20 No. 44 | November 18, 1994

Download PDF Visit The Full Archive

Related Articles

NCI-Approved CTEP Trials For The Month of June

June 29, 2012

OMB Revisions Would Kill 16 Center core Grants, Ban New Ones, Slash Noncompeting Funds 10 Percent

April 15, 1983

Urocidin May Provide Alternative To Cystectomy in BCG Cancers

May 27, 2011

NCI Programs: Coleman To Lead NCI’s New Radiation Oncology Program

February 5, 1999

Only 20 Percent Of At-Risk Patients Are Screened For HBV Before Therapy

November 25, 2011

Pretreatment with Azacitidine Achieves 28-Month Remission

August 30, 2013